The state of Nevada will receive $1.4 million as part of a $100 million settlement with drug maker Abbott Laboratories.
The settlement, which involves 44 other states and the District of Columbia, stems from allegations that the pharmaceutical company marketed a drug, Depakote, for uses other than what its label specifies.
As part of the investigation, Abbott Laboratories has agreed to change how it markets Depakote and will be restricted from advertising the drug for off-label uses not approved by the U.S. Food and Drug Administration.
"Pharmaceutical companies must promote and market drugs appropriately," said Nevada Attorney General Catherine Cortez Masto. "This settlement was reached because I felt Nevada consumers had not been adequately protected."
Depakote is approved for the treatment of seizure disorders, mania associated with bipolar disorder and prophylaxis of migraines. It is alleged the drug was being marketed as a remedy for schizophrenia, agitated dementia and the effects of autism.
The agreement marks the largest consumer protection-based pharmaceutical settlement ever reached.
Copyright 2012 KVVU (KVVU Broadcasting Corporation). All rights reserved.